Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... N.J. (PRWEB) May 21, 2015 ... circulation audit and been admitted to BPA Worldwide ... BPA Worldwide will track audience data for Specialty ... coverage. , “By becoming a member of ... dedication to providing our clients with the most ...
(Date:5/21/2015)... NEW YORK , May 21, 2015  Prima ... biotechnology company that is striving to become a leader ... of cancer, recently announced that the final CVac data ... has shown a clear trend for a clinically meaningful ... ("SOC") in second remission patients. In the ...
(Date:5/21/2015)... Calif. , May 21, 2015  The ... Orrin Hatch (R-UT) and Amy Klobuchar ... Extensions Now Accelerating Cures & Treatments, or OPEN ... rare disease patient advocacy organizations, this bipartisan legislation ... and affordable medicines to rare disease patients by ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... - Alfalight, Inc. , a Madison-based manufacturer ... markets, has been awarded $1.4 million in funding for ... program, sponsored by the Defense Advanced Research Projects ... is to increase a laser's power conversion efficiency -- ...
... so-called Dog Days of summer. Business slows. Indeed, in Europe, ... a state of suspended animation that will last until the ... out for attention. Work's grasp weakens. , ,Or does it? ... to a Monday morning mountain in my inbox and a ...
... - Gov. Jim Doyle on Monday expressed hope ... Majority Leader Bill Frist's recent decision to support removal ... , ,Doyle made his comments at the groundbreaking of ... also praised Wisconsin's medical development scene. , ,In remarks ...
Cached Biology Technology:Alfalight garners $1.4 million defense funding for diode program 2Leaving it all behind 2Doyle praises Frist's new stem cell research position 2Doyle praises Frist's new stem cell research position 3
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... touted for its beneficial effects on a range of human ... developing certain cancers. But it does not improve cholesterol levels, ... Hospital. A team of scientists has shown that, at least ... volunteers with vitamin D deficiency received mega-doses of vitamin D. ...
... Donald Danforth Plant Science Center will be hosting its ... Friday, September 28th, 2012. This year,s symposium will feature ... will present on a wide range of topics on ... synthetic and systems level explorations in biology that are ...
... three quarters of disposed electrical household appliances in Spain ... (SIG). A study at the University of Salamanca exposes ... waste management system and avoid payment. According to ... manufacturers of such products should recycle the waste they ...
Cached Biology News:Vitamin D supplements do not improve cholesterol as previous research suggested 2Danforth Plant Science Center hosts 14th Annual Fall Symposium 2More than 70% of electronic waste management is uncontrolled 2More than 70% of electronic waste management is uncontrolled 3
5 minutes from gel band to purified DNA...
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
Biology Products: